You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

ER , PR , HER2

Showing 1 - 25 of 6,028
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

TNBC - Triple-Negative Breast Cancer Trial (Alkaline Glucosodiene Molecules)

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Alkaline Glucosodiene Molecules
  • (no location specified)
Jul 14, 2023

Breast Cancer Trial in Sydney ([68Ga]GA-NeoB)

Recruiting
  • Breast Cancer
  • Sydney, New South Wales, Australia
    St Vincent's Hospital
May 22, 2023

Breast Cancer, Brain Metastases Trial in Guangzhou (Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant)

Recruiting
  • Breast Cancer
  • Brain Metastases
  • Palbociclib, Trastuzumab, Pyrotinib and Fulvestrant
  • Guangzhou, Guangdong, China
  • +1 more
Apr 24, 2022

HER2-positive Breast Cancer Trial in China (TQB2440 injection + Trastuzumab + Docetaxel, Perjeta + Trastuzumab + Docetaxel)

Active, not recruiting
  • HER2-positive Breast Cancer
  • TQB2440 injection + Trastuzumab + Docetaxel
  • Perjeta + Trastuzumab + Docetaxel
  • Chongqing, Chongqing, China
  • +5 more
Aug 3, 2023

Stage IV (Metastatic) Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Boston (NERATINIB,

Not yet recruiting
  • Stage IV (Metastatic) Breast Cancer
  • +5 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 25, 2021

Breast Cancer, HER2-negative Breast Cancer, ER Positive Breast Cancer Trial in Stanford (Infigratinib, Tamoxifen, Omnipaque 350)

Recruiting
  • Breast Cancer
  • +3 more
  • Stanford, California
    Stanford University
Feb 16, 2022

Metastatic Breast Cancer Trial in Athens

Recruiting
  • Metastatic Breast Cancer
    • Athens, Greece
      Hellenic Society of Medical Oncology
    Feb 9, 2021

    After Neoadjuvant Chemotherapy for Breast Cancer

    Recruiting
    • TN ER-/PR-/HER2- Breast Cancer
    • +3 more
    • Standard Trimodality Breast Imaging
    • Minneapolis, Minnesota
      University of Minnesota Masonic Cancer Center
    Aug 13, 2021

    Breast Cancer, HER2-positive Breast Cancer, ER Positive Breast Cancer Trial (Neratinib, Letrozole (L) or Anastrozole (A),

    Not yet recruiting
    • Breast Cancer
    • +3 more
    • (no location specified)
    Jan 11, 2022

    Metastatic Triple Negative Breast Cancer Trial in Birmingham (Combination of Veliparib + Lapatinib)

    Active, not recruiting
    • Metastatic Triple Negative Breast Cancer
    • Combination of Veliparib + Lapatinib
    • Birmingham, Alabama
      University of Alabama at Birmingham
    Feb 25, 2022

    Breast Cancer, Invasive Breast Cancer, ER-Negative PR-Negative HER2-Negative Breast Cancer Trial in Chapel Hill (Entinostat)

    Terminated
    • Breast Cancer
    • +2 more
    • Chapel Hill, North Carolina
      Lineberger Comprehensive Cancer Center at University of North Ca
    Mar 22, 2021

    HER2-positive Breast Cancer, ER-Negative Breast Cancer, PR-Negative Breast Cancer Trial in Belgium, France (Pertuzumab and

    Recruiting
    • HER2-positive Breast Cancer
    • +3 more
    • Pertuzumab and tratuzumab fixed dose combination
    • Trastuzumab emtansine
    • Auchenflower, Australia
    • +84 more
    Jan 16, 2023

    Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer Stage I Trial in Shanghai (FWD1802, palbocilib)

    Recruiting
    • Metastatic Breast Cancer
    • +3 more
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center
    Sep 26, 2023

    Metastatic Breast Cancer Trial in Shanghai (Trastuzumab, pyrotinib, Dalpiciclib)

    Not yet recruiting
    • Metastatic Breast Cancer
    • Shanghai, Shanghai, China
      Fudan University Shanghai Cancer Center Shanghai, China, 200032
    Oct 11, 2022

    Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

    Recruiting
    • Hormone Receptor Positive HER-2 Negative Breast Cancer
    • Shanghai, Shanghai, China
      Breast cancer institute of Fudan University Cancer Hospital
    Jun 12, 2023

    Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial

    Suspended
    • Anatomic Stage I Breast Cancer AJCC v8
    • +23 more
    • Short-Term Fasting
    • Chemotherapy
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Jan 23, 2023

    ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

    Recruiting
    • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
    • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
    • Montpellier, France
    • +1 more
    Nov 16, 2022

    Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago

    Not yet recruiting
    • Estrogen-receptor-positive Breast Cancer
    • +3 more
    • elacestrant, palbociclib, abemaciclib, ribociclib
    • Chicago, Illinois
      Northwestern University
    Sep 25, 2023

    ER+ HER2- Advanced Breast Cancer Trial in Chuo-ku, Kashiwa, Koto-ku (AZD9833)

    Active, not recruiting
    • ER+ HER2- Advanced Breast Cancer
    • Chuo-ku, Japan
    • +2 more
    Jan 24, 2023

    Advanced or Metastatic Breast Cancer Trial in Paris (Milademetan, Patient Reported Outcomes (PROs) and Health-Related Quality of

    Not yet recruiting
    • Advanced or Metastatic Breast Cancer
    • Milademetan
    • Patient Reported Outcomes (PROs) and Health-Related Quality of Life (HRQOL)
    • Paris, France
      Institut Curie
    Jun 27, 2023

    Breast Cancer, Cancer of the Breast Trial in Saint Louis (VENTANA MIB-1 Ki67 assay, Oncotype DX® Recurrence Score, PAM50-based

    Not yet recruiting
    • Breast Cancer
    • Cancer of the Breast
    • VENTANA MIB-1 Ki67 assay
    • +4 more
    • Saint Louis, Missouri
      Washington University School of Medicine
    Apr 18, 2023

    Relative Dose Intensity of Adjuvant Chemotherapy in Older ER+

    Not yet recruiting
    • Breast Cancer
      • (no location specified)
      Aug 21, 2023

      Invasive Breast Cancer, Triple Negative Breast Cancer, ER-Negative Breast Cancer Trial in Boston, Danvers, Newton (Sacituzumab

      Active, not recruiting
      • Invasive Breast Cancer
      • +4 more
      • Boston, Massachusetts
      • +4 more
      Oct 25, 2021

      Concordance of IHC4 Score Performed in Local or Central

      Active, not recruiting
      • Breast Neoplasm Female
      • IHC4 score
      • Nice, France
        Centre Antoine Lacassagne
      Feb 2, 2023

      HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving

      Completed
      • Breast Neoplasms
      • NET or NCT
      • Haidian, Beijing, China
        Peking University Cancer Hospital
      Dec 30, 2022